Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Clinipace, a clinical research organization, has announced that Inspire Pharmaceuticals has selected the company to manage and deploy two phase II studies for the ophthalmic prescription medicine, AzaSite. FDA has recently approved AzaSite for the treatment of bacterial conjunctivitis.
Subscribe to our email newsletter
Clinipace will offer technology driven clinical trial services to Inspire including data management, clinical monitoring, site management, regulatory document management, and biostatistical consulting.
The trail team will use Tempotm for Clinical Trials software from Clinipace to manage site initiation, patient enrollment and randomization, clinical data capture, monitoring trip reports, site management, and regulatory document tracking.
Chad Ice, Senior Director of clinical research at Inspire, said: “we share a common goal with Clinipace of changing the way we approach the clinical development process shifting away from some of the more traditional CRO processes and moving towards an integrated technology-driven model.
“With Clinipace, we plan to remove unnecessary layers of management and processes and We believe that Clinipace can help assure that communication with our clinical sites is much more seamless – one of the most vital links driving the success of our clinical trial process”, he added.